Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria

The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events. Autoimmune comorbidities (mainly thyroid-related) were associated with reduced drug survival, primarily due to lack of efficacy, whereas atopic comorbidities were associated with discontinuation after disease control, underscoring the need for improved endotype-driven treatment strategies.

Corresponding Author: Muhammed Elhadi, MBBCh, MSc, College of Medicine, Korea University, Anam-ro, Seongbuk-gu, Seoul 02841, South Korea (muhammed-elhadi@korea.ac.kr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.